Founder succession at Basic Pharma: SHS Capital acquires a majority stake
Bob Kool remains on board as a shareholder and member of the advisory board
Advertisement
Healthcare investor SHS Capital invests in Basic Pharma, a Dutch speciality pharmaceutical platform and full-service CDMO headquartered in Geleen. The investment provides a succession solution for the founder and aims to develop Basic Pharma into a leading European speciality pharma and dossier development platform for nasal sprays.
Founded in 2003 by pharmacist Bob Kool, Basic Pharma has evolved from a local contract manufacturer into an integrated pharmaceutical platform combining in-house product development, regulatory affairs, pharmacovigilance and GMP manufacturing at its facility in Geleen, the Netherlands, serving an international client base across prescription (Rx) and over-the-counter (OTC) pharmaceuticals as well as investigational medicinal products. A key differentiator is the company’s ability to develop, register and out-license product dossiers: under its “licence & supply” model, internally developed products are licensed to distributors and pharmaceutical partners while Basic Pharma retains exclusive manufacturing and market authorization rights, creating long-term customer relationships and strong recurring revenues. Basic Pharma holds a leading position in the Dutch nasal spray market and, thanks to its lean and highly efficient production set-up, offers its products at competitive prices, also internationally.
SHS Capital intends to accompany Basic Pharma as a growth partner in the coming years. The joint value creation plan focuses on strengthening the highly successful core business, driving operational excellence, further professionalising the organisation and accelerating international expansion, particularly in European markets with attractive pricing dynamics. In addition, Basic Pharma is well positioned as a platform for selective buy-and-build opportunities in the fragmented European CDMO landscape. Founder Bob Kool will continue to support the company and will remain involved as a shareholder and member of the Advisory Board.
“For more than two decades, we have built Basic Pharma into an integrated pharmaceutical platform with a strong team and loyal, long-standing customers,” says Bob Kool, founder and CEO of Basic Pharma. “It was very important to me to place the succession of my life’s work in the right hands. With SHS, we have found a highly experienced and specialised healthcare private equity fund that truly understands our business, values our people and shares our ambitions. I am delighted that Basic Pharma’s next chapter will be written together with such a knowledgeable partner, and I look forward to continuing to support the company in this exciting phase.”
“Basic Pharma is exactly the type of company we look for: a specialised European healthcare champion with a differentiated business model, proprietary dossiers and significant untapped international potential,” says Dr Cornelius Maas, Partner at SHS Capital. “We look forward to supporting the team in the next phase of growth, organically and through selective acquisitions.”
Other news from the department business & finance
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.